Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FGJT3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,747
Award facts
- Contract value 100% obligated
- $1,747.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,747.44 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 ml auto-injectable units. This firm fixed-price delivery order was issued on December 11, 2025, with an ultimate completion date of January 5, 2026, and does not utilize a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as the prime contractor with no identified subcontractors. The company will deliver the pharmaceutical product to Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and extends through December 31, 2036. The PPV-G GEN V represents part of a $30.3 billion acquisition strategy designed to provide Department of Defense military healthcare facilities worldwide with comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FGJT3?
SPE2DR26FGJT3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FGJT3 worth?
The government has obligated $1,747 on SPE2DR26FGJT3.
Is contract SPE2DR26FGJT3 an order under another contract?
Yes. SPE2DR26FGJT3 is a delivery order under SPE2DR25D9832, an indefinite delivery contract.
Was contract SPE2DR26FGJT3 competed?
The extent of competition for SPE2DR26FGJT3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award